Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.55 |
| ▸ | MAPT | P10636 | 10/20 | 0.55 |
| ▸ | LMNA | P02545 | 6/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | CCR4 | P51679 | 1/20 | 0.51 |
| ▸ | NSD2 | O96028 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.50 |
| ▸ | PRKCG | P05129 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21783687 | 0.85 | TNF (0.49) | ROCK2ROCK1ALDH1A1MAPTLMNA | |
| SCHEMBL29826581 | 0.81 | KEAP1 (0.65) | ROCK2ROCK1ALDH1A1MAPTLMNA | |
| SCHEMBL2912624 | 0.81 | KEAP1 (0.65) | ROCK2ROCK1ALDH1A1MAPTLMNA | |
| SCHEMBL2477664 | 0.81 | LMNA (0.58) | ROCK2ROCK1ALDH1A1MAPTLMNA | |
| SCHEMBL31629163 | 0.81 | LMNA (0.58) | ROCK2ROCK1ALDH1A1MAPTLMNA | |
| SCHEMBL23299515 | 0.80 | ALDH1A1 (0.51) | ROCK2ROCK1ALDH1A1MAPTLMNA | |
| SCHEMBL11142216 | 0.80 | ALDH1A1 (0.53) | ROCK2ROCK1ALDH1A1MAPTLMNA | |
| SCHEMBL2622218 | 0.80 | CCR4 (0.55) | ROCK2ROCK1ALDH1A1MAPTLMNA | |
| SCHEMBL11143217 | 0.80 | LMNA (0.62) | ROCK2ROCK1ALDH1A1MAPTLMNA | |
| SCHEMBL7355127 | 0.80 | CCR4 (0.48) | ROCK2ROCK1ALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| CN-118878514-A | Heterocyclic compounds for modulating NR2F6 | TES制药有限责任公司 | 2024-11-01 | — | — | CN | disclosed |
| WO-2024119122-A1 | CDK INHIBITORS AND METHODS AND USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2023278981-A1 | SYNTHESIS OF A BIS-MESYLATE SALT OF 4-AMINO-N-(1 -((3-CHLORO-2- FLUOROPHENYL)AMINO)-6-METHYLISOQUINOLIN-5-YL)THIENO[3,2- D]PYRIMIDINE-7-CARBOXAMIDE AND INTERMEDIATES THERETO | GENENTECH, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| CN-115427394-A | Heterocyclic compounds for modulating NR2F6 | TES制药有限责任公司 | 2022-12-02 | — | — | CN | disclosed |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| WO-2021226519-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021226458-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021226477-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2021-11-11 | — | — | WO | disclosed |
| US-7297695-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| US-6984647-B2 | Aminotetralin-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-10 | — | — | US | disclosed |
| US-20050187291-A1 | use of 2-(urea or thiourea)tetralins as analgesic or to treat pulmonary dysfunction | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-25 | — | — | US | disclosed |
| EP-1506166-A1 | AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | disclosed |
| US-20030236280-A1 | Aminotetralin-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-12-25 | — | — | US | disclosed |
| WO-2003097586-A1 | AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-27 | — | — | WO | disclosed |
| US-5254679-A | Containing a quaternized nitrogen | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-10-19 | — | — | US | disclosed |
| US-5049558-A | Quaternized nitrogen-heterocycle substituted | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-09-17 | — | — | US | disclosed |
| EP-0164944-B1 | CEPHALOSPORIN DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-07-11 | — | — | EP | disclosed |
| EP-0164944-A1 | Cephalosporin derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187291-A1 | use of 2-(urea or thiourea)tetralins as analgesic or to treat pulmonary dysfunction | TMEM109, UTS2R, GPR17 | ROCK2 4644/4885ROCK1 4232/4885ALDH1A1 1133/4885 |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | ROCK2 2207/4885ROCK1 3857/4885ALDH1A1 2328/4885 |
| US-20030236280-A1 | Aminotetralin-derived urea modulators of vanilloid VR1 receptor | UTS2R, TRPV6, TRPV1 | ROCK2 4858/4885ROCK1 4600/4885ALDH1A1 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.